No Data
Atopic Dermatitis: 2025 Pipeline Insights Report Covering 100+ Companies and 120+ Pipeline Drugs, Including ICP-332 (Innocare Pharma), APG777 (Apogee Therapeutics), and Barzolvolimab (Celldex Therapeutics)
GTJA: The Global competitiveness of domestic Innovative Drugs is becoming prominent, and the Operation turning point is approaching.
The current trend in the Innovative Drugs Industry is positive, with continuous marginal improvements. The negotiation time for medical insurance will be advanced in 2025, and the category C directory is expected to be released within the year. It is anticipated that the price drop for biosimilars in the centralized procurement will be moderate. Attention should be paid to recent academic conferences, and there is a bullish outlook on leading Innovative Drug companies.
[Hong Kong Stock Connect] INNOCARE (09969) rises over 9%. The clinical phase II results of orelizumab for treating RRMS show high effectiveness and safety.
Jingwu Financial News | INNOCARE (09969) stock price fluctuates upwards, currently reported at HKD 9.8, an increase of 9.38%, with a trading volume of HKD 0.339 billion. In terms of news, the company announced that its new BTK inhibitor, Orelabrutinib, has shown high efficacy and safety in the Phase II clinical trial for treating relapsing-remitting multiple sclerosis (RRMS). An 80 mg daily dose of Orelabrutinib has been determined for the Phase III clinical trial. At week 12, all three dose groups of Orelabrutinib showed a reduction in cumulative new Gd+T1 lesions in the brain compared to the placebo group.
InnoCare Pharma Anti-MS Drug Selected for Phase 3 Studies Following Efficacy, Safety Results
INNOCARE (688428.SH): Released phase II clinical data for the new BTK inhibitor, Orelabrutinib, at the forum.
INNOCARE (688428.SH) announced that the company will participate in the 10th Americas Multiple Sclerosis Treatment in 2025...
INNOCARE (688428.SH): Released Phase II clinical data on the use of Obtobrutinib for the treatment of relapsing-remitting multiple sclerosis at the 10th Annual Forum of the Americas Committee for Multiple Sclerosis Treatment and Research.
On February 26, Gelonghui reported that INNOCARE (688428.SH) announced that at the 10th Annual Forum of the Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) in 2025, new phase II clinical data for the novel BTK inhibitor Obeticholic Acid in the treatment of relapsing-remitting multiple sclerosis (referred to as 'RRMS') will be presented, with a live poster display scheduled for February 27 at Eastern Time (Poster Code: P094). The study results indicate that Obeticholic Acid demonstrates high efficacy in treating RRMS patients. A daily dose of 80 mg of Obeticholic Acid shows optimal effectiveness and
